This is a totally left field announcement, and shows how cutting edge the CORE NK platform is.
This is initiator sponsored trial, setup by Jennifer Eva Selfridge at Case Comprehensive Cancer Center University Hospitals Cleveland.
https://clinicaltrials.gov/ct2/show/NCT05400122
Which means that Chimeric out of pocket costs might be only the CORE NK manufacturing.
Fantastic update.
- Forums
- ASX - By Stock
- CHM
- Ann: First phase 1B trial of NK cells with IL-2 & Vactosertib
CHM
chimeric therapeutics limited
Add to My Watchlist
25.0%
!
0.5¢

Ann: First phase 1B trial of NK cells with IL-2 & Vactosertib, page-8
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
0.5¢ |
Change
0.001(25.0%) |
Mkt cap ! $10.07M |
Open | High | Low | Value | Volume |
0.4¢ | 0.5¢ | 0.4¢ | $11.08K | 2.623M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 4706271 | 0.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.5¢ | 14960701 | 24 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 4706271 | 0.004 |
42 | 27903271 | 0.003 |
15 | 13950505 | 0.002 |
10 | 50600000 | 0.001 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.005 | 14960701 | 24 |
0.006 | 13343479 | 16 |
0.007 | 3200000 | 3 |
0.008 | 8542434 | 6 |
0.009 | 2327672 | 4 |
Last trade - 11.14am 23/06/2025 (20 minute delay) ? |
Featured News
CHM (ASX) Chart |